Abstract 111P
Background
In China, fruquintinib is approved for third-line treatment of patients with metastatic colorectal cancer(mCRC). There are no prospective randomized controlled studies comparing the efficacy of fruquintinib and fruquintinib in combination with immune checkpoint inhibitors (ICIs). In this study, we aimed to compare the efficacy and safety of fruquintinib monotherapy versus combination with ICIs in MSS mCRC.
Methods
We retrospectively analyzed mCRC patients who received fruquintinib in Sun Yat-sen University Cancer Center from January 2020 to January 2022. The primary endpoints were overall survival (OS), progression-free survival (PFS) and adverse events. The secondary endpoints were objective remission rate (ORR) and disease control rate (DCR).
Results
A total of 184 patients with mCRC were included in this study, and 61 patients received ICIs combined with fruquintinib. Most patients received second line and above treatment before the study treatment. The ORR of fruquintinib combined with ICIs group (Group A, n=61) and fruquintinib group (Group B, n=123) were 14.3% and 3.6%; the DCR were 55.1% and 39.8%, respectively. Group A had a significant longer median PFS than Group B (3.9 months vs 3.3 months, P=0.015). However, the median OS was no significant difference between the two groups (mOS: 9.3 months vs 7.9 months, P=0.414). In the third line and above, there was no statistically significant difference in OS and PFS between the two groups. Multivariate analysis showed that baseline liver metastasis and lactate dehydrogenase (LDH)of≥313.3 were associated with shorter PFS in those 184 patients. Adverse effects of two groups were generally similar (91.8% vs 93.2%, P=0.738), and the most common adverse effects of two groups were the hand–foot skin reaction, hoarseness and hypertension. The probability of treatment-related adverse events (TRAEs)of grade 3 or higher was broadly similar in both groups (14.1% vs 14.6%, P=0.916).
Conclusions
In the real world, there was no difference in OS and in the incidence of adverse events between patients with MSS mCRC patients treated with fruquintinib monotherapy versus in combination with ICIs.
Clinical trial identification
NCT04005066.
Editorial acknowledgement
Legal entity responsible for the study
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract